Nguyen H. Tran - Concepedia

Author

Nguyen H. Tran

Also Known As

N H Tran, N. Tran, NGUYEN H. TRAN, Nguyen H Tran, Nguyen H. Tran, Nguyen Tran, Nguyễn Hồ Bảo Trân, Ngọc Bích Trần, Rondell P. Graham, Young Nyun Park

108

Publications

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Arizona Mayo Clinic in Florida Mayo Clinic WinnMed University of Michigan

About

Nguyen H. Tran is an author at Mayo Clinic in Arizona specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	184
2	Hepatology	2	2	28
3	Health Sciences	1	1	15
4	Cell Biology	1	1	21
5	Immunology	1	1	15

Nguyen H. Tran

Publications

365

Citations

H-Index

Page 1

	Year	Citations
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors Susan N. Payne, Molly E. Maher, Nguyen H. Tran, Oncogenesis	2015	71
PGE2 and LTB4 tissue levels in benign and cancerous prostates S. Larré, Nguyen H. Tran, Cheng Fan, Prostaglandins & Other Lipid Mediators UrologyTranslational BiologyGenitourinary CancerPathologyBenign Prostatic Hyperplasia	2008	51
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga Scott M. Thompson, Garima Suman, Michael Torbenson, Hepatology Communications	2021	45
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer Nguyen H. Tran, Vaibhav Sahai, Kent A. Griffith, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyRadiation MedicinePancreatic CancerRadiation TherapyMedicine	2019	37
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma Daniel H. Ahn, Pedro Luiz Serrano Usón, Peter Masci, Investigational New Drugs Surgical OncologyOncologyMedicineHepatobiliary TumorBiliary Cancer	2021	27
Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity Dan Jin, Nguyen H. Tran, Nagheme Thomas, PLoS ONE PharmacotherapyCell CycleTumor BiologyMedicinal ChemistryOncology	2019	21
Morphological heterogeneity in beta-catenin–mutated hepatocellular carcinomas: implications for tumor molecular classification Michael Torbenson, Chantal E. McCabe, Daniel R. O’Brien, Human Pathology Beta-catenin–mutated Hepatocellular CarcinomasTumor Molecular ClassificationMedicineHistopathologyPathology	2021	20
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma Michael H. Storandt, Jennifer Gile, Mathias Earl Palmer, Cancers ImmunologyPathologyMedian Overall SurvivalImmunotherapyOncology	2022	15
Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer S. Liddell, Sakti Chakrabarti, Grant Wintheiser, JCO Precision Oncology	2022	13
Systemic therapy in advanced hepatocellular carcinoma Joseph Ahn, Nguyen H. Tran, Ju Dong Yang Clinical and Molecular Hepatology HepatologyHepatocellular CarcinomaMedicineSystemic TherapyLiver Cancer	2023	13

Page 1